location: Home > english > NEWSROOM > August 2016 (2) >
Luqa Pharmaceuticals Partners With Mayoly Spindler To Distribute Meteospasmyl
source:admin time:2017-08-31


JULY 6TH 2016 Hong Kong, PRC – Luqa Pharmaceuticals (“Luqa” or the “Company”), the China focused specialty pharmaceutical company, announces that it has entered into an exclusive long-term agreement for the distribution rights of METEOSPASMYL (ALVERINE CITRATE + SIMETICONE) a product used for the symptomatic treatment of functional bowel disorders, especially those with bloating including Irritable Bowel Syndrome.

Meteospasmyl is an original and clinically proven combination of Alverine Citrate and Simeticone indicated against IBS. MeteoSpasmyl® is the only antispasmodic product which acts on visceral hypersensitivity and relieves quickly and durably pain/discomfort due to all the symptoms of IBS (spasms, bloating, bowel habit disorders), thanks to the association of alverin citrate and simethicone.

Luqa will be responsible for the sales, marketing and distribution in Hong Kong and Macau, with initial commercialisation expected during the second half of 2016. Luqa is already firmly established in the GI market with its prescription portfolio, which is actively promoted by the Company’s own sales force and distribution partners in Hong Kong and Macau.

Robert Braithwaite, Luqa’s CEO commented,

“We are extremely pleased to announce this transaction, which extends Luqa’s growing GI and specialty care portfolio. This addition extends our portfolio of solutions in prescription gastroenterology and enables us to further leverage our existing sales and marketing infrastructure in Hong Kong and Macau. It also has an immediate revenue impact for Luqa, but we expect considerable growth from this brand in the coming years.


About Luqa Pharmaceuticals

Luqa Pharmaceuticals is a China-focused company. It acquires, develops and commercialises innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. Luqa aims to become a leader in specialty care segments in China , Hong Kong and Macau.

For more information about Luqa Pharmaceuticals

Mr. Luis Juste Business Development Director

+86 15618684311

ljuste@luqapharma.com www.luqapharma.com


About Mayoly Spindler

Mayoly Spindler is a leading French company in the gastroenterology and dermocosmetic field Mayoly develops its own products, from drug design to marketing. This advantage, coupled with their power of innovation, enables them to establish in key geographic areas and to increase their market share internationally, developing unique strategic positions in emerging countries.